Company Overview
About Epinoma
Epinoma is a San Francisco-based biotech company engineering proteins that read and write epigenetic signals — developing protein tools for earlier cancer and disease detection through liquid biopsy (blood tests that detect disease-specific epigenetic marks) and therapeutic interventions that modify epigenetic states to treat disease without permanently altering DNA sequence. A Y Combinator S21 graduate backed by George Church (Harvard genetics pioneer), seedToB, and SeaX Ventures with $125,000 raised, Epinoma achieved $1 million in revenue in 2024 with an 8-person team, targeting the $50 billion blood test development market.
Business Model & Competitive Advantage
Epinoma's protein engineering platform designs novel proteins that can read specific epigenetic modifications (DNA methylation patterns, histone modifications) and write new epigenetic states at targeted genomic locations. Epigenetic marks — chemical modifications on DNA and histones that regulate gene expression without changing DNA sequence — are increasingly recognized as disease biomarkers and therapeutic targets. For liquid biopsy diagnostics, specific methylation patterns in circulating tumor DNA can indicate cancer type and stage earlier than traditional biomarkers. For therapeutics, epigenetic editing can silence oncogenes or activate tumor suppressor genes.
Competitive Landscape 2025–2026
In 2025, Epinoma competes in the epigenomics tools and liquid biopsy diagnostics market with Illumina (ILMN, sequencing instruments), Grail (Galleri multi-cancer early detection test), Exact Sciences (Oncotype), and epigenetic therapeutics companies including Constellation Pharmaceuticals (acquired by MorphoSys/Novartis) for epigenetic diagnostics and tools. The liquid biopsy market is rapidly growing as multi-cancer early detection (MCED) tests demonstrate clinical validity — Grail's Galleri test and similar platforms are generating significant commercial adoption. Epinoma's protein engineering approach to epigenetic tools could provide both better detection biomarkers and the therapeutic editing tools that convert diagnostic findings into treatment interventions. George Church's advisory role connects Epinoma to the Harvard synthetic biology ecosystem. The 2025 strategy focuses on commercializing the protein tools for research and diagnostic applications, building partnerships with diagnostics companies developing liquid biopsy assays, and advancing the epigenetic therapeutics platform toward clinical validation.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Epinoma is an emerging player bringing innovative solutions to the Healthcare market.
Enterprise Scale
With $50000M in revenue, Epinoma operates at enterprise scale with proven market validation.
Frequently Asked Questions
Not So Random Others
Yoneda Labs
Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit
Decoda Health
Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Grap
Fortuna Health
Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowi
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
AbbVie
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Sp
Compare Epinoma with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Epinoma? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Epinoma Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Epinoma vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →